Palvella Therapeutics, Inc. (NASDAQ: PVLA) is a Healthcare company (Biotechnology) with a market capitalization of $2.1B. The Maz Rating grades it against the other companies in its sector.
Palvella Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $144.35, Palvella Therapeutics, Inc. trades at 10.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -44.4%, return on invested capital of -31.3% and a free cash flow yield of -2.0%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 16.01. Over the past 52 weeks the share price ranged from $72.22 to $179.95, with a beta of -0.17.
Palvella Therapeutics, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 1 Strong Buy and 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.